



ASX Release
4th August 2025

Compumedics continues to expand into global pharmaceutical clinical trial market

Highlights

- Somfit sales to global pharmaceutical Contract Research Organisation (CRO) in USA and Orion Pharma in Europe
- Combined sales approaching \$2M
- Strong early traction in pharmaceutical sector highlights Somfit's potential beyond core HST (Home Sleep Testing) market

Compumedics Limited (ASX: CMP), a global medical device company specialising in sleep, brain, and ultrasonic blood flow monitoring, today announced that it has secured multiple Somfit sales to leading pharmaceutical and clinical research organisations across the USA and Europe, with combined revenues from these initial transactions now approaching \$2 million.

The first transaction was secured with one of the world's leading pharmaceutical Contract Research Organisations (CROs) for use in a major US-based clinical drug trial with one of the world's largest pharmaceutical companies. The second was with Orion Pharma, a global pharmaceutical company headquartered in Finland, for deployment of Somfit devices across a multi-country, multi-centre clinical study in Europe.

Both sales represent clear evidence of Compumedics' stated strategy to expand into adjacent markets, where Somfit's unique ability to collect direct EEG signals and deliver true sleep architecture insights offers a clear advantage over traditional home sleep testing systems.

These contracts further validate Somfit's clinical value proposition in the pharmaceutical sector, where understanding the effects of new drugs on sleep is an increasingly important regulatory and research requirement.

Executive Chairman and CEO Dr David Burton commented:

“These recent sales wins highlight the growing momentum we’re seeing for Somfit in new market segments. The pharmaceutical clinical trial market is an ideal adjacency for our technology, and these early contracts, approaching \$2 million in combined value, demonstrate Somfit’s versatility beyond traditional home sleep testing. This is another important step in building a diversified global business with multiple high growth pathways.”

Compumedics expects to build on this early traction, with continued engagement across major pharmaceutical companies, and research institutions globally.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton

Executive Chairman, CEO

P: +61 3 8420 7300

F: +61 3 8420 7399

David Lawson

Director, CFO

P: + 61 3 8420 7300

F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited’s Board of Directors